News Powered By:
- a collaborative partner.
CenterWatch News Online Headlines : February 26, 2015 9:32 am : Centerwatch
Pearl IRB, an Indianapolis-based provider of central IRB review services, has received accreditation by the Association for the Accreditation of Human Research Protection Programs (AAHRPP). Pearl IRB earned this distinction in December 2014 by demonstrating extensive safeguards in all levels of the research operations and abiding by high standards of excellence for all research.
CenterWatch News Online Headlines : February 26, 2015 9:30 am : Centerwatch
Roche and BioMed X, a collaboration model at the interface between academia and industry based in Heidelberg, Germany, have entered into a collaboration agreement to establish a research group focusing on the development of a novel sensor technology platform based on new nanomaterials such as graphene.
CenterWatch News Online Headlines : February 26, 2015 9:28 am : Centerwatch
Recursion Pharmaceuticals, an emerging biotech company founded in 2013 based on technology developed at the University of Utah, has been awarded $1.46 million from the NIH via the National Center for Accelerating Translational Sciences (NCATS). Just over half of the award is available in the first year; the rest will come through in year two pending availability of funds and project progress. The award will support the further development of Recursion’s Drug Screening Platform for hundreds of rare genetic diseases.
CenterWatch News Online Headlines : February 26, 2015 9:21 am : Centerwatch
Huntingdon Life Sciences (HLS) and Harlan Laboratories will formally merge under one brand to reflect a new integrated management structure and broader product and service offerings of the combined organizations.
CenterWatch News Online Headlines : February 26, 2015 7:12 am : Centerwatch
The FDA has approved Avycaz (ceftazidime-avibactam), a new antibacterial drug product, to treat adults with complicated intra-abdominal infections (cIAI), in combination with metronidazole, and complicated urinary tract infections (cUTI), including kidney infections (pyelonephritis), who have limited or no alternative treatment options.